Kadcyla® (ado-trastuzumab emtansine)

BL 125427

Kadcyla® (ado-trastuzumab emtansine)

BL 125427

U.S. License Holder:

Genentech

Date of License:

February-22-2013

Last Update:

December-09-2018

approved_indications FDA-Approved Indications


KADCYLA (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:

Received prior therapy for metastatic disease, or

Developed disease recurrence during or within six months of completing adjuvant therapy.

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

U.S. Patent No.
8,337,856 (Methods of Treatment Using Anti-ERbB Antibody-Maytansinoid Conjugates)

Patent Owner
Genentech, Inc.; Immunogen, Inc.

Petitioner(s)
Phigenix, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Composition of Matter

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
16-1544

IPR Status
Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal Dismissed

U.S. Patent No.
7,575,748 (Methods of Treatment Using Anti-ERbB Antibody-Maytansinoid Conjugates)

Patent Owner
Genentech, Inc.; Immunogen, Inc.

Petitioner(s)
Phigenix, Inc.

§ 102 Challenge
N

§ 103 challenge
Y

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

approved_indications U.S. Patent Litigations

PACER

Case No(s):

U.S. Patent Nos.
8,080,534 (Targeting PAX2 for the Treatment of Breast Cancer)

Plaintiffs
Phigenix, Inc.; MUSC Foundation For Research Development

Defendants
Genentech, Inc.

Status
Case Transferred to N.D. Cal. (5:15-cv-01238 (N.D. Cal.))

BPCIA
N

U.S. Patent Nos.
8,080,534 (Targeting PAX2 for the Treatment of Breast Cancer)

Plaintiffs
Phigenix, Inc.; MUSC Foundation For Research Development

Defendants
Genentech, Inc.

Federal Circuit Appeal(s)
17-2617; 18-1042 (Cross Appeal)

Status
Case Dismissed; Federal Circuit Appeal and Cross Appeal Pending

BPCIA
N

related articles Related News Articles


Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha